Bristol-Myers Squibb

Biocept CFO resigns; interim replacement named

Monday, August 24, 2015

Biocept, a San Diego-based molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, has announced the voluntary resignation of Bill Kachioff, senior vice president and chief financial officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim chief financial officer, effective immediately.

[Read More]

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]

Report: Pharma R&D pipeline value jumps 18% to $493 billion

Wednesday, June 17, 2015

Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the U.S. and Europe, fueling a projected 5% increase in global prescription sales over the next five years, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report from life science market intelligence firm Evaluate. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

[Read More]

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

[Read More]